• +86-0635-6175299
  • li_ye@inyelchem.com
    •
  • Company Details

     Shandong Haohong Biotechnology Co., Ltd.

     [Shandong,China]

    Business Type:Manufacturer

    Main Markets: Americas , Asia , East Europe , Europe , Middle East , North Europe , West Europe , Worldwide

    Exporter:71% - 80%

    Certs:Test Report, ISO9001

    Description:Upadacitinib Cas 1201187-44-1,Upadacitinib Cas 1428243-26-8,Upadacitinib Intermediate Cas 1201187-44-1,Upadacitinib Intermediate Cas 1428243-26-8

    Language

 Shandong Haohong Biotechnology Co., Ltd.

All
  • All
  • Title
All
  • All
  • Title
HomeProductsRheumatoid Arthritis RA DrugUpadacitinib Intermediates
PRODUCT CATEGORIES

Upadacitinib Intermediates

(Total 5 Products)
High Quality Cas 1428243-26-8

High Quality Cas 1428243-26-8

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: (3R,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate； (3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylicacidphenylmethylester; intermediateofabt594; (3R,4S)-benzyl3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate;...
Contact Now
Pharmaceutical Raw Material Cas 1201187-44-1

Pharmaceutical Raw Material Cas 1201187-44-1

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate； tert-butylN-[5-(4-methylbenzenesulfonyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl]carbamate; tert-butChemicalbookyl(5-(p-toluenesulfonyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate;...
Contact Now
Pharmaceutical Raw Material Cas 1428243-26-8

Pharmaceutical Raw Material Cas 1428243-26-8

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: (3R,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate； (3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylicacidphenylmethylester; intermediateofabt594; (3R,4S)-benzyl3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate;...
Contact Now
Upadacitinib Intermediate Cas 1428243-26-8

Upadacitinib Intermediate Cas 1428243-26-8

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: (3R,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate； (3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylicacidphenylmethylester; intermediateofabt594; (3R,4S)-benzyl3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate;...
Contact Now
Upadacitinib Intermediate Cas 1201187-44-1

Upadacitinib Intermediate Cas 1201187-44-1

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name: tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate； tert-butylN-[5-(4-methylbenzenesulfonyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl]carbamate; tert-butChemicalbookyl(5-(p-toluenesulfonyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate;...
Contact Now
Home > Products > Rheumatoid Arthritis RA Drug > Upadacitinib Intermediates

China Upadacitinib Intermediates Suppliers

Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate. Upadacitinib is marketed under the brand name RINVOQ™ for oral administration. It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.
 Shandong Haohong Biotechnology Co., Ltd.

Related Products List

Contact Us

Kelly
Name: Ms. Kelly
Email: li_ye@inyelchem.com
Tel: +86-0635-6175299
Address No.5,North Guandao street,Gaotang County, Liaocheng, Shandong

Mobile Site

Copyright © 2024  Shandong Haohong Biotechnology Co., Ltd. All rights reserved .  Privacy Policy

Home

Product

Whatsapp

About Us

Inquiry
Please Leave Us A Message

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Upload Attachment
Send